Want to see AI help cure the world? Convince more people to share their health data

Healthcare AI isn’t yet good enough to reliably deliver on its promises where it stands to make the biggest difference—and it doesn’t have enough high-quality data to get there anytime soon.

The promises getting called into question include speeding up drug development, personalizing medicine based on genomes and making basic diagnoses in regions of the world that lack doctors. Those doing the questioning include Dr. Soumya Swaminathan, chief scientist of the World Health Organization.  

“Health data is a public good, but people have to trust the WHO and governments that it won’t be used for commercial reasons without their consent or to discriminate against people,” Swaminathan says, according to a BBC News item posted June 28.

Swaminathan additionally warns of the risk for insufficiently fed and tested algorithms to find their way into smartphone apps, potentially doing more harm than good.

That risk may be greatest in regions of the world with plenty of smartphones but a dearth of doctors, she suggests.

Meanwhile, BBC reporter Matthew Wall points out, people around the world are reluctant to share their data even anonymously, making it hard to marshal the massive datasets needed to develop independently able algorithms and test them in clinical trials.

“[T]o maximize the undoubted benefits of AI in healthcare,” Wall writes, “we need to digitize as much health data as possible and persuade the world to share this data for the good of all.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”